Moderna (MRNA) surged about 177% after it and Merck (MRK) reported the first positive Phase 3 result for an mRNA cancer ...

Moderna just transformed from a cash-burning vaccine maker into a serious acquirer, and four biotech targets are already ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121 ...

Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.

Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home ...

Ahead of US stock trading that day, Moderna and Merck jointly announced the results of the Phase III INTerpath-001 clinical ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Merck and Moderna's personalised cancer vaccine shows promise against melanoma, reducing recurrence risk. This mRNA-based ...

Moderna and Merck's mRNA cancer vaccine marks a breakthrough in personalized oncology, with broad financial implications for ...

Operator: Good day, and thank you for standing by. Valneva presents its half year 2026 financial results. [Operator ...

Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an ...